NO20024735L - Anvendelse av fulvestrant for behandling av resistent brystkreft - Google Patents

Anvendelse av fulvestrant for behandling av resistent brystkreft

Info

Publication number
NO20024735L
NO20024735L NO20024735A NO20024735A NO20024735L NO 20024735 L NO20024735 L NO 20024735L NO 20024735 A NO20024735 A NO 20024735A NO 20024735 A NO20024735 A NO 20024735A NO 20024735 L NO20024735 L NO 20024735L
Authority
NO
Norway
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
NO20024735A
Other languages
English (en)
Other versions
NO329949B1 (no
NO20024735D0 (no
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024735(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20024735D0 publication Critical patent/NO20024735D0/no
Publication of NO20024735L publication Critical patent/NO20024735L/no
Publication of NO329949B1 publication Critical patent/NO329949B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024735A 2000-04-05 2002-10-02 Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft NO329949B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (3)

Publication Number Publication Date
NO20024735D0 NO20024735D0 (no) 2002-10-02
NO20024735L true NO20024735L (no) 2002-11-27
NO329949B1 NO329949B1 (no) 2011-01-31

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024735A NO329949B1 (no) 2000-04-05 2002-10-02 Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft

Country Status (29)

Country Link
US (2) US20030158166A1 (no)
EP (2) EP1586323A1 (no)
JP (1) JP2003528919A (no)
KR (1) KR100757764B1 (no)
CN (1) CN1431905A (no)
AT (1) ATE306270T1 (no)
AU (2) AU2001244372B2 (no)
BR (1) BR0109789A (no)
CA (1) CA2403608A1 (no)
CH (1) CH1272195H1 (no)
CZ (1) CZ303096B6 (no)
DE (1) DE60113975T2 (no)
DK (1) DK1272195T3 (no)
EE (1) EE05026B1 (no)
ES (1) ES2248300T3 (no)
GB (1) GB0008172D0 (no)
HK (1) HK1051498A1 (no)
HU (1) HU230064B1 (no)
IL (2) IL151932A0 (no)
IS (1) IS2869B (no)
MX (1) MXPA02009744A (no)
NO (1) NO329949B1 (no)
NZ (1) NZ539603A (no)
PL (1) PL201175B1 (no)
RU (1) RU2265438C2 (no)
SK (1) SK287779B6 (no)
UA (1) UA80388C2 (no)
WO (1) WO2001074366A1 (no)
ZA (1) ZA200207538B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
PL367624A1 (en) * 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
JP5256042B2 (ja) * 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
BR112013028890A2 (pt) * 2011-05-09 2017-01-31 Univ Virginia Patent Foundation composições e métodos para o tratamento de câncer
BR112013029758A2 (pt) 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
IL272924B2 (en) 2017-09-11 2024-01-01 Atossa Therapeutics Inc Methods for preparing and using endoxifen
EP3801553A4 (en) * 2018-05-24 2022-04-27 Kashiv Biosciences, LLC PRODRUGS OF FULVESTRANT
EP4110344A4 (en) * 2020-02-29 2024-03-13 The Univ Of Vermont USE OF THYROMIMETICS TO TREAT CANCER

Also Published As

Publication number Publication date
US20030158166A1 (en) 2003-08-21
ATE306270T1 (de) 2005-10-15
NO329949B1 (no) 2011-01-31
ZA200207538B (en) 2003-12-19
DK1272195T3 (da) 2006-01-16
EP1272195A1 (en) 2003-01-08
KR100757764B1 (ko) 2007-09-12
JP2003528919A (ja) 2003-09-30
HU230064B1 (hu) 2015-06-29
DE60113975T2 (de) 2006-06-22
HUP0300339A3 (en) 2009-01-28
CH1272195H1 (no) 2019-10-15
CZ20023309A3 (cs) 2003-02-12
EE200200574A (et) 2004-04-15
HK1051498A1 (en) 2003-08-08
MXPA02009744A (es) 2004-02-26
CN1431905A (zh) 2003-07-23
EE05026B1 (et) 2008-06-16
HUP0300339A2 (hu) 2003-06-28
EP1272195B1 (en) 2005-10-12
EP1586323A1 (en) 2005-10-19
SK287779B6 (sk) 2011-09-05
DE60113975D1 (de) 2006-02-23
PL201175B1 (pl) 2009-03-31
PL357936A1 (en) 2004-08-09
US20110183949A1 (en) 2011-07-28
IS6576A (is) 2002-10-01
NO20024735D0 (no) 2002-10-02
IL151932A (en) 2007-07-04
IS2869B (is) 2014-03-15
CA2403608A1 (en) 2001-10-11
GB0008172D0 (en) 2000-05-24
NZ539603A (en) 2008-02-29
CZ303096B6 (cs) 2012-04-04
BR0109789A (pt) 2003-01-21
RU2265438C2 (ru) 2005-12-10
AU2001244372B2 (en) 2006-02-16
AU4437201A (en) 2001-10-15
WO2001074366A1 (en) 2001-10-11
ES2248300T3 (es) 2006-03-16
KR20030007501A (ko) 2003-01-23
UA80388C2 (en) 2007-09-25
SK14292002A3 (sk) 2003-08-05
IL151932A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE305306T1 (de) Reboxetin zur behandlung von peripheren neuropathien
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
NO20024735L (no) Anvendelse av fulvestrant for behandling av resistent brystkreft
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
DK1063998T3 (da) Lægemiddel til profylakse og/eller behandling af mammarkarcinom indeholdende en steroidal aromataseinhibitor
LV12656B (lv) Arstniecibas lidzeklis un panemiens opija narkomanijas pacientu arstesanai
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
ATE338541T1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien

Legal Events

Date Code Title Description
MK1K Patent expired